Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma

WANG Yixin; HU Zongtao; ZHANG Yongkang; ZENG Ping; WANG Hongzhi

doi:10.3971/j.issn.1000-8578.2020.19.1112

Cancer Research on Prevention and Treatment > 2020 > 47(4): 298-302. > DOI: 10.3971/j.issn.1000-8578.2020.19.1112

WANG Yixin, HU Zongtao, ZHANG Yongkang, ZENG Ping, WANG Hongzhi. Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 298-302. DOI: 10.3971/j.issn.1000-8578.2020.19.1112

Citation:

PDF (3387 KB)

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma

WANG Yixin^{1, 2},
HU Zongtao^{1, 2},
ZHANG Yongkang¹,
ZENG Ping¹,
WANG Hongzhi^{1, 2, ,}

1.
Department of Oncology, Cancer Hospital, Chinese Academy of Sciences, Hefei 230031, China
2.
Anhui Provincial Key Laboratory of Medical Physics and Technology, Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China

More Information

Corresponding author:
WANG Hongzhi, E-mail: wanghz@hfcas.ac.cn
Received Date: September 01, 2019
Revised Date: December 19, 2019
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To observe the short-term clinical effect and total survival of advanced hepatocellular carcinoma patients treated with PD-1.
Methods
We retrospectively analyzed the clinical data of 48 patients with advanced hepatocellular carcinoma treated with PD-1 monoclonal antibody (observation group) and 55 patients with advanced hepatocellular carcinoma treated with apatinib mesylate(control group). Short-term clinical effect, overall survival and adverse reactions were analyzed.
Results
The AFP, ALT, AST, ECOG, Child-Paugh score, objective remission rate and disease control rate in the observation group were better than those in the control group (P < 0.05), and the overall survival in the observation group (95%CI: 7.24-8.64 months) was significantly longer than that in the control group (95%CI: 5.13-6.39 months) (P < 0.05). There were significant differences in rashes, nausea, vomiting and adverse reactions of hypertension between two groups (P < 0.05).
Conclusion
Compared with apatinib mesylate, PD-1 could improve the short-term clinical efficacy and prolong the overall survival of patients with advanced hepatocellular carcinoma.
- Hepatocellular carcinoma,
- Immunotherapy,
- Targeted therapy,
- PD-1

FullText(HTML)

References (20)

References

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]	Huang ZY, Liang BY, Xiong M, et al. Long-term Outcomes of Repeat Hepatic Resection in Patients with Recurrent Hepatocellular Carcinoma and Analysis of Recurrent Types and Their Prognosis: A Single-Center Experience in China[J]. Ann Surg Oncol, 2012, 19(8): 2515-2525.
[3]	Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy[J]. J Cell Physiol, 2019, 234(10): 16824-16837.
[4]	Liu B, Arakawa Y, Yokogawa R, et al. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes[J]. PLoS One, 2018, 13(4): e0194594.
[5]	Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer[J]. Curr Opin Investig Drugs, 2010, 11(12): 1354-1359.
[6]	Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
[7]	Liu B, Song Y, Liu D. Recent development in clinical applicationsof PD-1 and PD-L1 antibodies for cancer immunotherapy[J]. J Hematol Oncol, 2017, 10(1): 174.
[8]	Chang H, Jung W, Kim A, et al. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellularcarcinoma[J]. APMIS, 2017, 125(8): 690-698.
[9]	Butte MJ, Keir ME, Phamduy TB, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses[J]. Immunity, 2007, 27(1): 111-122.
[10]	Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort[J]. Aliment Pharmacol Ther, 2019, 49(10): 1323-1333.
[11]	Peng S, Zhang Y, Peng H, et al. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib[J]. Cancer Lett, 2016, 373(2): 193-202.
[12]	Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs Today (Barc), 2015, 51(4): 223-229.
[13]	秦叔逵, 白玉贤, 欧阳学农, 等.阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J].临床肿瘤学杂志, 2017, 22(12): 1057-1065. Qin SK, Bai YX, Ouyang XN, et al. Apatinib for patients with advanced hepatocellular carcinoma: a randomised, open-label, multicentre, phaseⅡ clinical trial[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2017, 22(12): 1057-1065.
[14]	Crocenzi TS, Ei-Khoueiry AB, Yau TC, et al. Nivolumab (nivo) in sorafenib(sor)-naive and -experienced pts with advanced hepatocellular carcinoma(HCC): CheckMate 040 study[J]. J Clin Oncol, 2017, 35: 4013.
[15]	Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)[J]. Oncol Lett, 2017, 14(5): 5671-5680.
[16]	Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2016, 27(7): 1362.
[17]	Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. N Engl J Med, 2015, 373(3): 288-290.
[18]	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028.
[19]	Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treatedadvanced non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(18): 2004-2012.
[20]	Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60: 190-209.

[1]	SHAN Baoen. Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 833-841. DOI: 10.3971/j.issn.1000-8578.2023.22.1423
[2]	QIAO Shishi, KONG Tiandong, YU Dan, YANG Zhen, PAN Yanfeng, ZHAO Lingdi. A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 293-297. DOI: 10.3971/j.issn.1000-8578.2023.22.0852
[3]	YAN Guangning, YU Ling, LAI Xuwen, YE Danli, WANG Wei, WANG Zhuocai. Correlation Between PD-1/CTLA-4 Expressions with C linicopathological Features and Prognosis of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 63-68. DOI: 10.3971/j.issn.1000-8578.2023.22.0483
[4]	QI Lin, ZHANG Zhao, WANG Suyun, LIU Guimin, WANG Rui, FU Jianzhu, CHENG Zhiyong. Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1021-1027. DOI: 10.3971/j.issn.1000-8578.2022.22.0188
[5]	CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
[6]	LAI Yanliang, GENG Yan, YANG Bingquan. Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1035-1040. DOI: 10.3971/j.issn.1000-8578.2021.21.0365
[7]	YU Lin, LI Guangping, ZHOU Changyu, FU Huaying. Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 794-798. DOI: 10.3971/j.issn.1000-8578.2021.20.1449
[8]	MA Yinjuan, YANG Xiaying, WANG Ying, WANG Xuan, PAN Yaozhu. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 647-651. DOI: 10.3971/j.issn.1000-8578.2021.21.0108
[9]	WANG Yufeng, YAO Nan, WANG Jun, MIN Guangtao. Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 346-352. DOI: 10.3971/j.issn.1000-8578.2020.19.0950
[10]	ZOU Hanhui, Li Tao. Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 141-146. DOI: 10.3971/j.issn.1000-8578.2020.19.0945

Cited By

Cited by

Periodical cited type(12)

1.	梅琪，袁牧，钱景瑜，刘若宇，谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察. 蚌埠医学院学报. 2024(01): 51-54+58 .
2.	李丽敏，王璐，曹阳博，刘栋利，陈鹏飞. 肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析. 癌症进展. 2024(01): 72-75 .
3.	费睿成，亓民. PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果. 实用中西医结合临床. 2024(10): 16-19 .
4.	刘小梅，钟梅，刘浩，易军，王洪云. 晚期肝癌免疫相关治疗的获益和不良反应临床研究. 基层医学论坛. 2023(19): 20-22+35 .
5.	何晓锐，王淑红. 阿替利珠单抗联合贝伐珠单抗治疗晚期肝癌的临床效果. 临床医学研究与实践. 2023(27): 29-32 .
6.	陈方红，刘娱，边界. PD-1抑制剂治疗肝癌患者的临床疗效及ECOG-PS评分联合Child-Pugh分级对肿瘤超进展的预测价值. 广西医学. 2023(15): 1800-1806 .
7.	郭稳稳，程昌盛，吴燕，林文东，赖辉强，黄吉荣，龙高云. 安罗替尼治疗晚期肝癌的疗效及预后的影响因素. 临床与病理杂志. 2022(08): 1822-1828 .
8.	殷云飞，鲁邱阳. 抗PD-1单抗对中晚期肝癌患者近期疗效、外周血T淋巴细胞亚群指标的影响. 中国医学创新. 2021(13): 19-22 .
9.	李冰妍，陈林会，郑颖娟，梁天嵩，杨道科. 程序性死亡受体1抑制剂治疗远处转移鼻咽癌疗效观察. 肿瘤基础与临床. 2021(03): 207-211 .
10.	朱风婷，曾江正，姜靖雯，陈学武，张慧. 卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究. 中国药业. 2021(15): 38-41 .
11.	王俊旗，徐锋. 程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展. 中华普通外科学文献(电子版). 2021(04): 304-308 .
12.	鄢清元，熊巍，杨文平. 晚期肝癌患者索拉非尼分子靶向治疗的有效性及对疾病控制率的影响研究. 中国医学创新. 2021(29): 173-177 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1501) PDF downloads (536) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma